Trial Outcomes & Findings for Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline (NCT NCT01977729)

NCT ID: NCT01977729

Last Updated: 2016-05-16

Results Overview

Youth outcome will be assessed on a global level using the Clinical Global Impression (CGI) Severity Scale, ranging from 1 (not at all) to 7 (among the most extremely ill patients). Higher ratings indicate greater anxiety symptom severity. The CGI Improvement Scale ranges from 1 (very much improved) to 7 (very much worse). Lower ratings indicate greater improvement on anxiety symptom severity. A CGI Improvement Scale rating of 1 or 2 indicates clinically meaningful improvements in anxiety symptom severity.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

1 participants

Primary outcome timeframe

20 weeks from enrollment

Results posted on

2016-05-16

Participant Flow

Participant milestones

Participant milestones
Measure
All Participants
Only one participant was recruited, but never randomized.
Overall Study
STARTED
1
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
All Participants
Only one participant was recruited, but never randomized.
Overall Study
Study terminated
1

Baseline Characteristics

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=1 Participants
Age, Categorical
<=18 years
1 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
1 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 20 weeks from enrollment

Population: Medication was never given, and tests were never done.

Youth outcome will be assessed on a global level using the Clinical Global Impression (CGI) Severity Scale, ranging from 1 (not at all) to 7 (among the most extremely ill patients). Higher ratings indicate greater anxiety symptom severity. The CGI Improvement Scale ranges from 1 (very much improved) to 7 (very much worse). Lower ratings indicate greater improvement on anxiety symptom severity. A CGI Improvement Scale rating of 1 or 2 indicates clinically meaningful improvements in anxiety symptom severity.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 20 weeks from enrollment

Population: Study was terminated before randomization.

Multidimensional Anxiety Scale for Children (MASC-2; Self-report and Parent completed). Treatment outcome will be assessed on a specific symptom level from the youth's and parent's perspective using the MASC-2. The MASC-2 consists of 50 items across 5 factors: Separation Anxiety/Phobias, Generalized Anxiety Disorder, Social Anxiety, Obsessions \& Compulsions, and Harm Avoidance. MASC T-scores less than 65 indicate the child is no longer in the clinical range of anxiety symptoms.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 20 weeks from enrollment

Population: No data collected.

Positive and Negative Affect Scale for Children (PANAS-C). Negative affect (NA) will be assessed using the NA subscale on the PANAS-C. The 15 NA items (e.g., sad, miserable) on the 27-item PANAS-C are scored 1 (very slightly or not at all) to 5 (extremely). Higher scores in the NA subscale indicate higher levels of negative affect.

Outcome measures

Outcome data not reported

Adverse Events

CBT With SRT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Switch to SRT Alone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Wendy Silverman

Yale University

Phone: (203) 737-7053

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place